{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:19:13Z","timestamp":1762420753777,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"iNOVA4Health\u2014Programme in Translational Medicine and the Associated Laboratory","award":["UID\/04462","LS4FUTURE"],"award-info":[{"award-number":["UID\/04462","LS4FUTURE"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia\/Minist\u00e9rio da Educa\u00e7\u00e3o, Ci\u00eancia e Inova\u00e7\u00e3o"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Burkitt lymphoma is a rare, aggressive B-cell neoplasm with frequent central nervous system (CNS) involvement, treated with intensive multidrug regimens associated with rituximab. The aim of this study was to assess the efficacy, safety, and feasibility of the LMB protocol in adults with BL in a real-world setting. Methods: We included 55 patients with BL diagnosis according to the 2008 WHO classification, treated with LMB protocol associated with rituximab. Low-risk patients (no bone marrow or CNS involvement) were treated in the group B arm, while high-risk patients were placed in group C, which was further stratified by age and CNS infiltration. Results: Thirty-four patients (62%) were treated in group B and 21 patients (38%) were treated in group C, with a median age of 34 years (16\u201377). Extranodal infiltration was present in 71% patients, including 11 (20%) with CNS involvement. After a median follow up time of 7 years, the complete remission rate was 85%, and progression-free and overall survival at 3 years were 79% and 84%, respectively. Patients with CNS infiltration had an inferior survival rate (55% at 3 years). Grade 3\u20134 toxicities were frequent, mainly hematologic, infectious, and mucosal. Treatment required substantial supportive care, including 1604 transfusions and 4696 days of hospitalization. Patients over 60 years had poorer outcomes and higher toxicity. Conclusions: The LMB protocol demonstrated high survival rates in adult BL, although at the cost of significant toxicity and considerable health care resource utilization. Outcomes remained suboptimal in patients with CNS involvement despite treatment intensification.<\/jats:p>","DOI":"10.3390\/cancers17172914","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T09:51:21Z","timestamp":1757065881000},"page":"2914","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intensive Treatment in Adult Burkitt Lymphoma with Lymphome Malin B (LMB) Regimen: Excellent Outcomes Despite Substantial Toxicity and Supportive Care Demands"],"prefix":"10.3390","volume":"17","author":[{"given":"Ivan","family":"Dlouhy","sequence":"first","affiliation":[{"name":"Hematology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisboa, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Viegas","sequence":"additional","affiliation":[{"name":"Hematology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisboa, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00eas","family":"Coelho","sequence":"additional","affiliation":[{"name":"Hematology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisboa, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Ionita","sequence":"additional","affiliation":[{"name":"Hematology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisboa, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Hematology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisboa, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6232-1596","authenticated-orcid":false,"given":"Jos\u00e9","family":"Cabe\u00e7adas","sequence":"additional","affiliation":[{"name":"Pathology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisboa, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6993-2450","authenticated-orcid":false,"given":"Maria Gomes","family":"da Silva","sequence":"additional","affiliation":[{"name":"Hematology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisboa, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"ref_1","unstructured":"WHO Classification of Tumours Editorial Board (2024). WHO Classification of Tumours: Haematolymphoid Tumours, International Agency for Research on Cancer (IARC). [5th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2020006926","article-title":"Burkitt Lymphoma in the Modern Era: Real-World Outcomes and Prognostication across 30 US Cancer Centers","volume":"137","author":"Evens","year":"2021","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.3324\/haematol.2020.270876","article-title":"Outcomes of Burkitt Lymphoma with Central Nervous System Involvement: Evidence from a Large Multicenter Cohort Study","volume":"106","author":"Zayac","year":"2021","journal-title":"Haematologica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3324\/haematol.2020.278181","article-title":"Be Mindful of the Central Nervous System in Burkitt Lymphoma","volume":"106","author":"Roschewski","year":"2021","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1093\/annonc\/mdt414","article-title":"A Multicenter Phase II Study Incorporating High-Dose Rituximab and Liposomal Doxorubicin into the Lymphoma","volume":"24","author":"Evens","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with Hyper-CVAD plus Rituximab for the Treatment of Adult Burkitt and Burkitt-Type Lymphoma or Acute Lymphoblastic Leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","article-title":"Rituximab and Dose-Dense Chemotherapy for Adults with Burkitt\u2019s Lymphoma: A Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"387","author":"Ribrag","year":"2016","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/cncr.27918","article-title":"Dose-Intensive Chemotherapy Including Rituximab in Burkitt\u2019s Leukemia or Lymphoma Regardless of Human Immunodeficiency Virus Infection Status","volume":"119","author":"Ribera","year":"2013","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.20.00303","article-title":"Multicenter Study of Risk-Adapted Therapy with Dose-Adjusted EPOCH-R in Adults with Untreated Burkitt Lymphoma","volume":"38","author":"Roschewski","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-017-3167-7","article-title":"Treatment of Sporadic Burkitt Lymphoma in Adults, a Retrospective Comparison of Four Treatment Regimens","volume":"97","author":"Oosten","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdi403","article-title":"Burkitt Lymphoma in Adults: A Prospective Study of 72 Patients Treated with an Adapted Pediatric LMB Protocol","volume":"16","author":"Casassus","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","article-title":"The Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Oncologie P\u00e9diatrique LMB89 Protocol: Highly Effective Multiagent Chemotherapy Tailored to the Tumor Burden and Initial Response in 561 Unselected Children with B-Cell Lymphomas and L3 Leukemia","volume":"97","author":"Patte","year":"2001","journal-title":"Blood"},{"key":"ref_13","unstructured":"Swerdlow, S.H., Campo, E., Lee Harris, N., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., and Vardiman, J.W. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Internacional Agency for Research on Cancer (IARC). [4th ed.]."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993). A Predictive Model for Aggressive Non-Hodgkin\u2019s Lymphoma. N. Engl. J. Med., 329, 987\u2013994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1200\/JCO.20.03288","article-title":"Burkitt Lymphoma International Prognostic Index","volume":"39","author":"Olszewski","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_17","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer. [4th ed.]."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.20143","article-title":"Intensive Chemotherapy with and without Cranial Radiation for Burkitt Leukemia and Lymphoma: Final Results of Cancer and Leukemia Group B Study 9251","volume":"100","author":"Rizzieri","year":"2004","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.clml.2021.03.012","article-title":"Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies","volume":"21","author":"Leonart","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bjh.15262","article-title":"Excellent Real-World Outcomes of Adults with Burkitt Lymphoma Treated with CODOX-M\/IVAC plus or Minus Rituximab","volume":"181","author":"Zhu","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2016.70.0765","article-title":"Minimal Loss of Lifetime for Patients with Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months after Treatment: A Danish Population-Based Study","volume":"35","author":"Jakobsen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/1120009X.2018.1535771","article-title":"Treatment Outcomes of Adult Burkitt Lymphoma: Results with a Modified LMB Protocol in Brazil and Feasibility of Outpatient Administration","volume":"30","author":"Belesso","year":"2018","journal-title":"J. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00277-009-0729-3","article-title":"Treatment Outcome of Adult Patients with Burkitt Lymphoma: Results Using the LMB Protocol in Korea","volume":"88","author":"Choi","year":"2009","journal-title":"Ann. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.5045\/kjh.2011.46.2.96","article-title":"Treatment Outcomes in Children with Burkitt Lymphoma and L3 Acute Lymphoblastic Leukemia Treated Using the Lymphoma Malignancy B Protocol at a Single Institution","volume":"46","author":"Park","year":"2011","journal-title":"Korean J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1182\/bloodadvances.2022007475","article-title":"Safety and Efficacy of a Dose-Dense Short-Term Therapy in Patients with MYC-Translocated Aggressive Lymphoma","volume":"6","author":"Ferreri","year":"2022","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.hoc.2016.07.009","article-title":"Update on Burkitt Lymphoma","volume":"30","author":"Dunleavy","year":"2016","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e966","DOI":"10.1016\/S2352-3026(23)00279-X","article-title":"R-CODOX-M\/R-IVAC versus DA-EPOCH-R in Patients with Newly Diagnosed Burkitt Lymphoma (HOVON\/SAKK): Final Results of a Multicentre, Phase 3, Open-Label, Randomised Trial","volume":"10","author":"Chamuleau","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3324\/haematol.2023.283342","article-title":"Feasibility and Outcomes after Dose Reduction of Immunochemotherapy in Young Adults with Burkitt Lymphoma and Leukemia: Results of the BURKIMAB14 Trial","volume":"109","author":"Ribera","year":"2024","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1182\/blood.2019004099","article-title":"The Treatment of Burkitt Lymphoma in Adults","volume":"137","author":"Crombie","year":"2021","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.12736","article-title":"Improved Efficacy Using Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Aggressive Lymphomas: Cancer and Leukemia Group B Study 10002","volume":"165","author":"Rizzieri","year":"2014","journal-title":"Br. J. Haematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/17\/2914\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:14:13Z","timestamp":1762420453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/17\/2914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":30,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cancers17172914"],"URL":"https:\/\/doi.org\/10.3390\/cancers17172914","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,9,5]]}}}